The clinical puzzle, stated without the sales pitch
Spaceflight-associated neuro-ocular syndrome (SANS) is a recognized vision risk in long-duration crews. Idiopathic intracranial hypertension (IIH) is a terrestrial disorder of raised intracranial pressure, typically in young women with obesity, that produces papilledema and can threaten vision. Both involve the optic nerve head, both invite speculation about cerebrospinal fluid dynamics, and both have attracted genetic hypotheses. The temptation is to assume they share a cause and that one-carbon pathway variants explain who develops SANS.
That assumption is doing more work than the evidence supports. The strongest documented genetic thread in the astronaut literature is an association between one-carbon pathway polymorphisms and post-flight ophthalmic changes. The IIH literature I can point to here is about thrombophilia and hypofibrinolysis, not one-carbon metabolism. Those are different hypotheses about different mechanisms. Reading one as corroboration of the other is a category error dressed as translational insight.
What follows is an appraisal, not a screening recommendation. I will state what the retrieved sources report, separate that from interpretation, and describe what evidence would be needed before either finding becomes clinically actionable.
What the NASA one-carbon work reported
The relevant record is a NASA Technical Reports Server abstract (document 20150020960) describing work by Smith and colleagues on the Nutritional Status Assessment protocol. Two findings matter.
First, the biochemical finding. Serum concentrations of homocysteine, cystathionine, 2-methylcitric acid, and methylmalonic acid were significantly higher—by 25 to 45 percent—in astronauts with ophthalmic changes than in those without. The abstract states these differences existed before, during, and after flight. Serum folate was lower during flight in the affected group. Preflight cystathionine and 2-methylcitric acid, and mean in-flight folate, correlated with post-flight refractive change.
Second, the genetic finding. A follow-up analysis examined five polymorphisms in MTRR, MTHFR, SHMT, and CBS in 49 astronauts. The number of G alleles at MTRR 66 and C alleles at SHMT1 1420 both contributed to the odds of visual disturbances. The authors concluded that they document an association between these polymorphisms and spaceflight-induced vision changes, and that individuals with an altered one-carbon pathway may be predisposed to ophthalmic damage during flight.
Note the verbs. The abstract reports an association and a contribution to odds. It does not report a validated prediction model, a sensitivity and specificity, or a prospective test of genotype-first screening. The pre-flight presence of biochemical differences is interesting because it weakens a purely in-flight exposure explanation, but it does not establish causation. A marker that differs before exposure can reflect diet, baseline B-vitamin status, or population stratification as easily as a causal pathway.
The biology the abstract invokes—and its limits
One-carbon metabolism supplies methyl groups for DNA methylation, nucleotide synthesis, and the remethylation of homocysteine to methionine. Folate and vitamins B12 and B6 are cofactors. Variants in MTHFR, MTRR, SHMT1, and CBS can shift flux through these reactions, and elevated homocysteine or methylmalonic acid is a standard clinical signal of impaired function.
That is a coherent pathway. It is not a demonstrated mechanism of SANS. The abstract’s own framing is predisposition—an altered pathway may render an astronaut more susceptible to anatomic or physiologic changes. The intermediate steps between a polymorphism and optic disc edema, globe flattening, or choroidal folds are not established in the retrieved record. Anyone who tells you the pathway is proven is telling you something the source does not say.
There is also a practical confound worth naming. B-vitamin status at landing was itself a significant predictor of ophthalmic outcomes in the same analysis. Genotype and nutritional status are correlated in real cohorts, and diet on orbit is not a controlled variable. A genetic association that survives adjustment for measured folate and B12 is more persuasive than one that does not; the abstract does not give us enough to judge that.
What the IIH literature actually examined
The IIH study retrieved here is Glueck and colleagues’ prospective assessment of thrombophilia and hypofibrinolysis in men with IIH, published in Clinical and Applied Thrombosis/Hemostasis in 2005. Ten consecutively referred men with IIH were matched 2-to-1 by age and race to healthy male controls. The investigators tested four thrombophilic and one hypofibrinolytic gene variant—factor V Leiden, prothrombin G20210A, MTHFR C677T, platelet glycoprotein IIb/IIIa, and the PAI-1 4G/5G promoter polymorphism—alongside coagulation measures.
Their proposed mechanism is microthrombi, associated with thrombophilia-hypofibrinolysis, occluding arachnoid villi and reducing cerebrospinal fluid resorption. The authors describe heritable hypofibrinolysis and heritable and acquired thrombophilia as appearing, speculatively, to be treatable etiologies of IIH in men.
Read that carefully. MTHFR C677T appears in the panel, but the abstract does not report it as the finding. The reported signals are in PAI-1 and coagulation measures. The authors themselves use the word speculatively. And the cohort is ten men—a population that is atypical for IIH, which is predominantly a disorder of women with obesity. This is a hypothesis-generating study in a selected sample, not a genetic architecture of IIH.
So the honest comparison is this: the astronaut work centers on one-carbon metabolism and B-vitamin status; the retrieved IIH work centers on coagulation and fibrinolysis. They are not the same hypothesis. A clinician who cites the IIH paper as support for a one-carbon model of SANS has not read it closely.
Why the conflation happens, and why it matters
Both conditions involve the optic nerve head and both are associated with raised intracranial pressure in at least some patients. That phenotypic overlap is real and worth studying. But phenotypic similarity is not mechanistic identity. IIH is defined by elevated opening pressure without a mass lesion; SANS is a constellation of ocular findings in astronauts whose intracranial pressure is often not measurably elevated. The overlap in imaging is a reason to compare the two literatures, not a reason to merge them.
The conflation also has a clinical cost. If a flight surgeon or a neurologist treats a candidate polymorphism as a shared predictor, they may over-reassure a low-risk genotype or over-restrict a high-risk one. Neither the astronaut abstract nor the IIH paper supports that use. The astronaut finding is an odds contribution in 49 people; the IIH finding is a speculative mechanism in ten.
An appraisal habit for candidate genetic predictors
When a paper proposes a genotype as a predictor of an exposure-related outcome, three questions separate signal from noise.
Was the genotype measured before the outcome? In the astronaut work, the polymorphism analysis was a follow-up to a biochemical finding, and the abstract does not state whether the genetic analysis was pre-specified. Pre-specification matters because it limits the space for chance associations among five variants and multiple ophthalmic endpoints.
Was the comparison group comparable? The IIH study matched on age and race but used healthy controls rather than a comparison group with elevated intracranial pressure from another cause. That design can identify associations but cannot distinguish a cause of IIH from a marker of the population that develops it.
Is the reported effect an odds contribution or a validated risk model? An odds contribution tells you a variant is over- or under-represented. A risk model tells you how often it is right. Only the second is a screening tool. Neither retrieved study provides the second.
A hypothetical illustration, clearly hypothetical and not a case: a flight surgeon weighing a candidate polymorphism for a crew member should treat it as one input among measured biochemical and imaging variables—pre-flight folate and B12, in-flight ophthalmic surveillance, post-flight optical coherence tomography—until a prospective model exists. The genotype alone does not carry the decision.
What would move either claim from association to utility
For SANS, the needed study is a prospective cohort with genotype measured before flight, standardized ophthalmic endpoints defined in advance, and adjustment for B-vitamin status, carbon dioxide exposure, fluid shifts, and radiation dose. The cohort would need to be large enough to support out-of-sample validation. The astronaut population is small, which argues for international pooling and for pre-registered analysis plans rather than post hoc exploration.
For IIH, the needed work is a replication of the thrombophilia-hypofibrinolysis findings in a representative cohort—including women, who make up most cases—with a comparison group that has elevated intracranial pressure from other causes. A one-carbon hypothesis for IIH would require its own study; the retrieved paper does not provide one.
Until then, the defensible statement is narrow. In astronauts, variants in MTRR and SHMT1 have been associated with post-flight visual disturbances in a small cohort, alongside biochemical differences in one-carbon metabolites. In men with IIH, thrombophilic and hypofibrinolytic variants have been associated with the condition in a small, speculative study. Neither finding is a predictive test, and neither corroborates the other.
FAQ
Does a MTHFR variant cause SANS?
No study retrieved here establishes that. The astronaut abstract reports an association between MTRR 66 and SHMT1 1420 and visual disturbances, not a causal role for MTHFR. MTHFR was among the genes examined, but the reported signals were elsewhere.
Should astronauts be genotyped before flight?
Not on the basis of this evidence. The abstract reports an odds contribution in 49 people without a validated risk model. Genotyping as a screening tool would require prospective validation with standardized endpoints and adjustment for nutritional and environmental confounders.
Is IIH a useful model for SANS?
It is a useful comparison for imaging and cerebrospinal fluid dynamics, but the retrieved IIH genetic literature examines coagulation, not one-carbon metabolism. Treating the two as a shared genetic story overstates what either source shows.
What should a clinician take from the biochemical finding?
That one-carbon metabolites differed before, during, and after flight in astronauts with ophthalmic changes is a reason to measure folate and B12 status in relevant cohorts and to include them as covariates in genetic analyses. It is not a reason to treat or restrict individuals on genotype alone.
Sources
Smith SM, Gregory JF, Zeisel SH, Gibson CR, Mader TH, Kinchen J, Ueland P, Ploutz-Snyder R, Heer M, Zwart SR. Risk of Visual Impairment and Intracranial Hypertension After Space Flight: Evaluation of the Role of Polymorphism of Enzymes Involved in One-Carbon Metabolism. NASA Technical Reports Server, document 20150020960. https://ntrs.nasa.gov/search.jsp?R=20150020960
Glueck CJ, Goldenberg N, Golnik K, Sieve L, Wang P. Idiopathic intracranial hypertension: associations with thrombophilia and hypofibrinolysis in men. Clinical and Applied Thrombosis/Hemostasis. 2005;11(4):441–448. https://scholar.barrowneuro.org/neurology/1576/